Stryker Co. (NYSE:SYK) Shares Sold by Cary Street Partners Asset Management LLC

Cary Street Partners Asset Management LLC decreased its position in Stryker Co. (NYSE:SYK) by 1.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,359 shares of the medical technology company’s stock after selling 70 shares during the period. Cary Street Partners Asset Management LLC’s holdings in Stryker were worth $2,297,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Greenwood Capital Associates LLC raised its position in Stryker by 2.3% in the third quarter. Greenwood Capital Associates LLC now owns 22,964 shares of the medical technology company’s stock worth $8,296,000 after acquiring an additional 519 shares in the last quarter. FSM Wealth Advisors LLC increased its holdings in shares of Stryker by 2.8% in the 3rd quarter. FSM Wealth Advisors LLC now owns 1,888 shares of the medical technology company’s stock valued at $682,000 after purchasing an additional 52 shares in the last quarter. Moloney Securities Asset Management LLC acquired a new stake in shares of Stryker in the third quarter valued at about $1,133,000. Quintet Private Bank Europe S.A. boosted its holdings in Stryker by 24.4% during the third quarter. Quintet Private Bank Europe S.A. now owns 7,230 shares of the medical technology company’s stock worth $2,612,000 after buying an additional 1,418 shares in the last quarter. Finally, PDS Planning Inc grew its position in Stryker by 5.5% during the third quarter. PDS Planning Inc now owns 1,422 shares of the medical technology company’s stock worth $514,000 after buying an additional 74 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Stryker news, VP M Kathryn Fink sold 7,347 shares of the business’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the transaction, the vice president now owns 10,042 shares in the company, valued at $3,685,213.16. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, VP M Kathryn Fink sold 7,347 shares of the company’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total value of $2,696,202.06. Following the completion of the transaction, the vice president now directly owns 10,042 shares in the company, valued at approximately $3,685,213.16. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Viju Menon sold 600 shares of Stryker stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the sale, the insider now directly owns 9,069 shares in the company, valued at $3,219,495. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 10,068 shares of company stock valued at $3,693,972. Company insiders own 5.50% of the company’s stock.

Stryker Trading Down 0.1 %

SYK stock opened at $366.90 on Tuesday. Stryker Co. has a 52 week low of $266.93 and a 52 week high of $374.63. The company has a market cap of $139.87 billion, a price-to-earnings ratio of 39.32, a PEG ratio of 2.77 and a beta of 0.91. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. The business has a fifty day simple moving average of $360.43 and a 200-day simple moving average of $344.64.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.77 by $0.10. The company had revenue of $5.49 billion during the quarter, compared to analyst estimates of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm’s revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.46 earnings per share. On average, equities research analysts expect that Stryker Co. will post 12.06 EPS for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were given a $0.80 dividend. This represents a $3.20 annualized dividend and a dividend yield of 0.87%. The ex-dividend date was Monday, September 30th. Stryker’s payout ratio is currently 34.30%.

Analysts Set New Price Targets

SYK has been the topic of several research analyst reports. Citigroup boosted their price target on Stryker from $406.00 to $411.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Needham & Company LLC lifted their price target on Stryker from $393.00 to $409.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Canaccord Genuity Group increased their price objective on shares of Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Wells Fargo & Company increased their price target on shares of Stryker from $381.00 to $405.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. Finally, Truist Financial lifted their price objective on Stryker from $370.00 to $380.00 and gave the stock a “hold” rating in a research report on Wednesday, October 30th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $393.65.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.